ArticleOphthalmology and therapy2026
Combined Light-Heavy Silicone Oil Endotamponade Compared with Heavy or Light Silicone Oil Endotamponade for Complex Rhegmatogenous Retinal Detachment: A Randomized Controlled Trial.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo compare the clinical outcomes and postoperative complications of combined light-heavy silicone oil (L-HSO), heavy silicone oil (HSO), and light silicone oil (LSO) endotamponade for complex rhegmatogenous retinal detachment (RRD) with superior and inferior retinal breaks.
methodsIn this prospective randomized controlled trial, 90 patients with primary complex RRD involving superior and inferior retinal breaks and proliferative vitreoretinopathy (PVR) grade C or higher were randomized to receive L-HSO, HSO, or LSO endotamponade after pars plana vitrectomy. Ultimately, 74 patients (74 eyes) completed the 12-month follow-up and were included in the final statistical analysis. The primary outcome was primary anatomical success rate. Secondary exploratory outcomes included best-corrected visual acuity (BCVA), intraocular pressure (IOP), and postoperative complications.
resultsDuring the follow-up period, no statistically significant differences in primary anatomical success rates were observed among the three groups, although the combined L-HSO group showed a numerically higher primary anatomical success rate (100.0%). In addition, exploratory analyses suggested better BCVA in the combined L-HSO group than in the HSO group before removal of silicone oil (ROSO) and at 6 months after ROSO than in the LSO group at 6 months after ROSO (P < 0.05); no significant differences were observed at 12 months after ROSO. Regarding postoperative complications, the combined L-HSO group showed lower incidences of cataract progression, emulsified silicone oil droplets adhering to the posterior capsule, silicone oil emulsification in the vitreous cavity, anterior PVR, and elevated IOP than the HSO group (all P < 0.05).
conclusionsCombined L-HSO endotamponade may represent a potential endotamponade strategy for complex RRD with superior and inferior retinal breaks. Although the combined L-HSO group showed a numerically higher primary anatomical success rate and potentially favorable functional and safety findings, these results should be interpreted as exploratory and require confirmation in adequately powered studies. CLINICAL
trial registrationChinese Clinical Trial Registry identifier: ChiCTR2600132242.
Indexed as
Identifiers
42867597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.